{"nctId":"NCT01040728","briefTitle":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","startDateStruct":{"date":"2010-01"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":122,"armGroups":[{"label":"Olodaterol (BI1744) Low","type":"EXPERIMENTAL","interventionNames":["Drug: Olodaterol (BI1744) Low"]},{"label":"Olodaterol (BI1744) High","type":"EXPERIMENTAL","interventionNames":["Drug: Olodaterol (BI1744) High"]},{"label":"Tiotropium 18 mcg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tiotropium 18 mcg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (for Olodaterol (BI1744)l)","Drug: Placebo (for Tiotropium)"]}],"interventions":[{"name":"Olodaterol (BI1744) Low","otherNames":[]},{"name":"Olodaterol (BI1744) High","otherNames":[]},{"name":"Tiotropium 18 mcg","otherNames":[]},{"name":"Placebo (for Olodaterol (BI1744)l)","otherNames":[]},{"name":"Placebo (for Tiotropium)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Patients willing to participate with confirmed diagnosis of COPD\n* 40 years of age or older\n* having a 10 pack year smoking history\n* able to perform serial pulmonary function tests\n* able to use both a Dry powder inhaler (DPI) and Respimat device\n\nExclusion criteria:\n\n* Significant other disease\n* clinically relevant abnormal hematology, chemistry, or urinalysis\n* history of asthma\n* diagnosis of thyrotoxicosis\n* paroxysmal tachycardia related to beta agonists\n* history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year\n* active tuberculosis, cystic fibrosis, clinically evident bronchiectasis\n* significant alcohol or drug abuse\n* pulmonary resection\n* taking oral beta adrenergics\n* taking unstable oral steroids\n* daytime oxygen\n* enrolled in rehabilitation program\n* enrolled in another study or taking investigational products\n* pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control\n* those who are not willing to comply with pulmonary medication washouts","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit for the first period, just prior to administration of the first morning dose of randomized treatment. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.008","spread":"0.019"},{"groupId":"OG001","value":"0.189","spread":"0.019"},{"groupId":"OG002","value":"0.213","spread":"0.019"},{"groupId":"OG003","value":"0.213","spread":"0.019"}]}]}]},{"type":"PRIMARY","title":"FEV1 Area Under Curve 12-24h (AUC 12-24h) Response After Six Weeks of Treatment","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit for the first period, just prior to administration of the first morning dose of randomized treatment. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.059","spread":"0.018"},{"groupId":"OG001","value":"0.094","spread":"0.018"},{"groupId":"OG002","value":"0.111","spread":"0.018"},{"groupId":"OG003","value":"0.105","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 h (AUC 0-24h) Response After Six Weeks of Treatment","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose at the first randomized treatment visit for the first period. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.033","spread":"0.019"},{"groupId":"OG001","value":"0.142","spread":"0.018"},{"groupId":"OG002","value":"0.158","spread":"0.018"},{"groupId":"OG003","value":"0.159","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response After First Dose of Treatment","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of the treatment at the first treatment visit for the first period. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FEV1 AUC 0-3h was calculated from 0-3hours post-dose using the trapezoidal rule, divided by the observation time (3 h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.018","spread":"0.018"},{"groupId":"OG001","value":"0.232","spread":"0.017"},{"groupId":"OG002","value":"0.256","spread":"0.017"},{"groupId":"OG003","value":"0.169","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response After Six Weeks of Treatment","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of treatment for the first period. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FEV1 AUC 0-3h was calculated from 0-3hours post-dose using the trapezoidal rule, divided by the observation time (3 h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.011","spread":"0.020"},{"groupId":"OG001","value":"0.225","spread":"0.019"},{"groupId":"OG002","value":"0.255","spread":"0.020"},{"groupId":"OG003","value":"0.246","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response","description":"Response was defined as change from baseline. Study baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of treatment for the first period. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after the first dose of treatment. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.076","spread":"0.019"},{"groupId":"OG001","value":"0.313","spread":"0.019"},{"groupId":"OG002","value":"0.342","spread":"0.019"},{"groupId":"OG003","value":"0.251","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response","description":"Response was defined as change from baseline. Study baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of treatment for the first period. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after the last dose after six weeks of treatment. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.082","spread":"0.020"},{"groupId":"OG001","value":"0.290","spread":"0.020"},{"groupId":"OG002","value":"0.325","spread":"0.020"},{"groupId":"OG003","value":"0.325","spread":"0.020"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response","description":"Response was defined as change from baseline. Study baseline trough FEV1 was defined as the mean of the available pre-dose trough FEV1 values prior to first dose of treatment for the first period. Trough values were the mean of values obtained 23h and 23 h 50 min after the last dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":"0.019"},{"groupId":"OG001","value":"0.137","spread":"0.019"},{"groupId":"OG002","value":"0.146","spread":"0.019"},{"groupId":"OG003","value":"0.161","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to first dose of treatment for the first period. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.006","spread":"0.035"},{"groupId":"OG001","value":"0.324","spread":"0.034"},{"groupId":"OG002","value":"0.321","spread":"0.035"},{"groupId":"OG003","value":"0.364","spread":"0.035"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to first dose of treatment for the first period. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.109","spread":"0.036"},{"groupId":"OG001","value":"0.169","spread":"0.035"},{"groupId":"OG002","value":"0.155","spread":"0.036"},{"groupId":"OG003","value":"0.192","spread":"0.035"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to first dose of treatment for the first period. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.057","spread":"0.036"},{"groupId":"OG001","value":"0.247","spread":"0.035"},{"groupId":"OG002","value":"0.226","spread":"0.036"},{"groupId":"OG003","value":"0.278","spread":"0.035"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of treatment for the first period. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.053","spread":"0.035"},{"groupId":"OG001","value":"0.423","spread":"0.034"},{"groupId":"OG002","value":"0.419","spread":"0.034"},{"groupId":"OG003","value":"0.316","spread":"0.034"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of treatment for the first period. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.044","spread":"0.035"},{"groupId":"OG001","value":"0.388","spread":"0.034"},{"groupId":"OG002","value":"0.397","spread":"0.035"},{"groupId":"OG003","value":"0.414","spread":"0.034"}]}]}]},{"type":"SECONDARY","title":"Peak FVC (0-3h) Response","description":"Response was defined as change from baseline. Study baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of treatment for the first period. Peak FVC (0-3h) was obtained within 0 - 3 hours after the last am dose of study drug after 6 weeks of treatment. Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.191","spread":"0.037"},{"groupId":"OG001","value":"0.526","spread":"0.036"},{"groupId":"OG002","value":"0.537","spread":"0.037"},{"groupId":"OG003","value":"0.569","spread":"0.037"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response","description":"Response was defined as change from baseline. Study baseline trough FVC was defined as the mean of the available pre-dose trough FVC values prior to first dose of treatment for the first period. Trough values were the mean of obtained 23 h and 23 h 50 min after the last dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with treatment and period as fixed effects and patient as a random effect and study baseline as a continuous covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.001","spread":"0.037"},{"groupId":"OG001","value":"0.243","spread":"0.036"},{"groupId":"OG002","value":"0.215","spread":"0.037"},{"groupId":"OG003","value":"0.255","spread":"0.037"}]}]}]},{"type":"SECONDARY","title":"Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG","description":"Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":109},"commonTop":["Nasopharyngitis","Chronic obstructive pulmonary disease"]}}}